Current Report Filing (8-k)
May 09 2017 - 4:08PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
______________
FORM 8-K
______________
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
The Securities Exchange Act of 1934
Date of
Report (Date of Earliest Event Reported):
May
9, 2017
______________
Foundation
Medicine, Inc.
(Exact
name of registrant as specified in its charter)
______________
Delaware
|
|
001-36086
|
|
27-1316416
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
150 Second Street
|
|
|
Cambridge, MA
|
|
02141
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code
(617) 418-2200
Not Applicable
(Former
name or former address, if changed since last report)
______________
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions:
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
______________
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 or Rule
12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act. ☒
Item 2.02. Results of Operations and Financial Condition.
On May 9, 2017, Foundation Medicine, Inc. issued a press release
announcing its financial and operating results for the quarter ended
March 31, 2017. A copy of the press release is being furnished as
Exhibit 99.1 to this Report on Form 8-K.
The information in this Report on Form 8-K and Exhibit 99.1 attached
hereto is intended to be furnished and shall not be deemed “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the “Exchange Act”) or otherwise subject to the liabilities of
that section, nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the Exchange
Act, except as expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.
|
Description
|
99.1
|
Press release issued by Foundation Medicine, Inc. dated May 9, 2017,
furnished hereto.
|
SIGNATURES
Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
|
|
|
Date:
|
May 9, 2017
|
|
FOUNDATION MEDICINE, INC.
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Jason Ryan
|
|
|
|
|
|
Name: Jason Ryan
|
|
|
|
|
|
Title: Chief Financial Officer
|
|
EXHIBIT INDEX
Exhibit No.
|
Description
|
99.1
|
Press release issued by Foundation Medicine, Inc. dated May 9, 2017,
furnished hereto.
|
Foundation Medicine, Inc. (NASDAQ:FMI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Foundation Medicine, Inc. (NASDAQ:FMI)
Historical Stock Chart
From Apr 2023 to Apr 2024